Wallerian degeneration of physically injured axons involves a well-defined molecular pathway linking loss of axonal survival factor NMNAT2 to activation of prodegenerative protein SARM1. Manipulating the pathway through these proteins led to the identification of non-axotomy insults causing axon degeneration by a Wallerian-like mechanism, including several involving mitochondrial impairment.
INTRODUCTION
Studies of axon degeneration following axotomy (Wallerian degeneration) and of the axon-protective protein WLD S have led to the discovery of critical endogenous regulators of the mechanisms resulting in axon degeneration (Conforti et al. 2014; Gerdts et al. 2016; Llobet Rosell and Neukomm 2019 ). The current model predicts that the pathway regulating Wallerian degeneration (Wallerian pathway) is activated by the loss in the axon of the labile nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2), a nicotinamide adenine dinucleotide (NAD)-synthesising enzyme. Axonal NMNAT2 levels decline within a few hours when its transport and/or synthesis are impaired (Gilley and Coleman 2010) . Downstream of NMNAT2 depletion, the pro-degenerative protein sterile alpha and TIR motif-containing protein 1 (SARM1) executes the degeneration program (Osterloh et al. 2012; Gilley et al. 2015; Gerdts et al. 2015; Loreto et al. 2015) . To date, expression of WLD S /NMNATs (which substitute for endogenous NMNAT2 loss) and SARM1 depletion are the most effective means to block the Wallerian pathway and preserve axons in mammals.
There is still debate about how NMNAT2 loss leads to SARM1 activation but the rise in its substrate, NMN, appears to be important , 2017 Loreto et al. 2015; Cohen 2017; Zhao et al. 2019) as well as the fall in its product, NAD (Gerdts et al. 2015; Sasaki et al. 2016; Essuman et al. 2017) .
Most studies on the Wallerian pathway have used a physical injury model, but there is clear evidence that related degenerative mechanisms can be activated by many non-injury stresses (Conforti et al. 2014 ). However, the vast majority of non-axotomy models were performed when a more comprehensive understanding of the Wallerian pathway was lacking and were mostly identified as being Wallerian-like by targeting just a single step in the pathway (either by expressing of WLD S /NMNATs or, more J o u r n a l P r e -p r o o f recently, by Sarm1 deletion). Both WLD s and SARM1 have the potential to influence other cellular mechanisms, such as nuclear NAD synthesis and innate immunity, respectively, so involvement of the Wallerian pathway is best supported by multiple lines of evidence.
The link between mitochondria and the Wallerian pathway is particularly intriguing.
Mitochondrial dysfunction is a common theme in a wide group of neurodegenerative disorders in which axon degeneration is central, including Parkinson's disease (PD), Charcot-Marie-Tooth disease, hereditary spastic paraplegia and Friedrich's ataxia (Court and Coleman 2012) . We and others have previously shown that mitochondria contribute to the later stages of Wallerian degeneration, where the axotomy itself activates the Wallerian pathway (Barrientos et al. 2011; Loreto et al. 2015) .
However, mitochondrial depolarisation, caused by the mitochondrial uncoupler Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), also leads to degeneration of uninjured axons (Loreto et al. 2015) , which is rescued by Sarm1 deletion (Summers et al. 2014) . Additional studies, both in vitro and in vivo, link the Wallerian pathway to mitochondrial impairment. Wld S mice are protected against nigrostriatal axon degeneration after intraperitoneal administration of the mitochondrial complex-1 inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
MATERIAL AND METHODS
All studies conformed to the institution's ethical requirements in accordance with the 1986 Animals (Scientific Procedures) Act. 
Primary neuronal cultures

Acquisition of phase contrast images and quantification of axon degeneration
Phase contrast images were acquired on a DMi8 upright fluorescence microscope and rabbit anti-SCG10 (10586-1-AP Proteintech, 1:3000). Mouse anti β-actin was used as a loading control (A5316 Sigma, 1:5000). Quantification of band intensity was determined by densitometry using ImageJ.
NMNAT2 axonal transport
Dissociated SCG neurons were microinjected using a Zeiss Axiovert S100 microscope with an Eppendorf FemtoJet microinjector and Eppendorf TransferMan ® micromanipulator. Plasmids were diluted in 0.5x PBS (without CaCl 2 and MgCl 2 ) and filtered using a Spin-X filter (Costar 
Determination of NMN and NAD levels
Following treatment with CCCP, Sarm1 -/-SCG ganglia were separated from their neurites with a scalpel. Neurites and cell bodies were washed in ice-cold PBS and rapidly frozen in dry ice and stored at −80 °C until processed for measuring NMN and NAD. Briefly, pyridine and adenine nucleotides were extracted by sonication in Maximum height achieved was graded into 5 mm intervals, flies that climbed less than 5 cm were scored zero, and any fly that exceeded 5 cm was awarded the maximum score. This was repeated 3 times at 60 sec intervals and an average score given for that vial.
Statistical analysis
Appropriate statistical testing of data was performed using Prism (GraphPad Software, La Jolla, USA). ANOVA with Tukey's, Sidak's or Bonferroni's post hoc correction (as applicable), and log-rank (Mantel-Cox) test were used in this study. The n numbers in each individual experiment and the tests used are described in the figure legends. A p value < 0.05 was considered significant (****, p<0.0001; ***, p<0.001; **, p<0.01; *, p<0.05; NS, non-significant).
J o u r n a l P r e -p r o o f
RESULTS
Multiple regulators of the Wallerian pathway rescue axon degeneration caused by mitochondrial depolarisation
The mitochondrial uncoupler CCCP is widely used to trigger mitochondrial depolarisation and assess the effects of mitochondrial impairment on cellular viability (Ly et al. 2003) . Previous work by us and others demonstrated that sympathetic and sensory primary neurons exposed to CCCP undergo disruption of mitochondrial membrane potential and axon degeneration (Summers et al. 2014; Loreto et al. 2015) , providing a good experimental model to study mitochondrial dysfunction leading to axon degeneration.
A dose-response experiment in superior cervical ganglion (SCG) neurons confirmed previous observations and allowed us to determine the most appropriate concentration of CCCP to use across the study. 50µM CCCP induces full mitochondrial depolarization within minutes after its addition (Loreto et al. 2015 ) and a dramatic depletion of ATP levels within the first 2 hr ( Fig. 1A) . Importantly, it consistently promoted neurite degeneration when measured at 24 hr post-application
We then tested whether this degenerative process could be rescued by regulators of the Wallerian pathway. Consistent with previous studies (Summers et al. 2014) , we found that Sarm1 -/-SCG neurites were strongly protected against CCCP toxicity ( Fig.   1D ,E). WLD S expression was highly protective too at this concentration ( Fig. 1F ,G).
Our findings demonstrate that the degeneration of axons following mitochondrial depolarisation can be delayed by multiple regulators of the Wallerian pathway.
J o u r n a l P r e -p r o o f
Journal Pre-proof
Mitochondrial depolarisation leads to depletion of axonal NMNAT2
NMNAT2 depletion in axons has been proposed as an initial step that triggers the activation of the Wallerian pathway (Gilley and Coleman 2010; Gilley et al. 2015; Loreto et al. 2015; Walker et al. 2017) . We therefore tested whether CCCP treatment led to NMNAT2 depletion in neurites (which were uninjured until immediately prior to harvesting separately from their cell bodies) and found that levels of this protein in neurites rapidly decline from 2 hr after CCCP addition ( Fig. 2A,B ). Loss of NMNAT2 occurred before any visible morphological damage to neurites (Fig. 2C) , also confirmed by the absence of changes to -actin levels ( Fig. 2A ).
We have recently reported that lowering the expression of NMNAT2 increases axonal vulnerability to several stresses (Gilley et al. 2019) . To test whether lowering NMNAT2 expression impairs the ability to withstand mitochondrial impairment, SCG neurons from mice with around 60% (Nmnat2 +/gtE ) and 30% (Nmnat2 gtBay/gtE ) of wild type Nmnat2 mRNA levels in whole brain (Gilley et al. 2019 ) were exposed to CCCP.
We found a significant acceleration of the degeneration process compared to wild type neurons, with clear morphological damage appearing as early as 4 hr in Nmnat2 gtBay/gtE neurites ( Fig. 2D,E) .
These data suggest that mitochondrial uncoupling activates the Wallerian pathway at an early step and, together with the protection afforded by WLD S (Fig. 1F,G) , they indicate that axonal NMNAT levels modulate axon survival after mitochondrial depolarisation.
NMNAT2 depletion reflects impairment of both axonal transport and synthesis
We next investigated the cause of NMNAT2 depletion after CCCP treatment. Being a labile protein with a half-life of less than an hour (Milde et al. 2013) , any cellular process that impairs its replenishment in axons would lead to a rapid decrease in J o u r n a l P r e -p r o o f axonal levels. Two potential mechanisms are a deficiency in axonal transport and/or altered synthesis, both of which are ATP-dependent. The finding that NMNAT2 levels also declined in the cell body/ganglia fraction after 4-8 hr of CCCP addition ( Fig. 3A,B ) suggests that synthesis of the protein is impaired (although enhanced protein degradation cannot be ruled out). However, the NMNAT2 decrease in the cell body fraction was much less marked than that in neurites ( Fig. 2A,B ), suggesting that impaired protein synthesis is not the only mechanism contributing to the depletion in the neurites.
We next explored whether CCCP alters NMNAT2 axonal transport. We microinjected GFP-tagged NMNAT2 and followed changes in its axonal transport parameters. We found a significant reduction of the percentage of motile NMNAT2 vesicles at 4 and 8
hr after CCCP addition ( Fig. 3C,D) . This may also explain the slight recovery of NMNAT2 levels in cell bodies at 8 hr after CCCP addition following the decline at 4 hr ( Fig. 3A,B) , as any NMNAT2 that is synthesised would be less efficiently transported into neurites and would accumulate in cell bodies instead. The overall reduction in axonal transport of NMNAT2 appeared to be a result of a combination of impaired anterograde, retrograde and bidirectional transport, although separately none of the individual parameters reached statistical significance ( Fig. 3E ). Impairment of axonal transport following CCCP is unlikely to be specific for NMNAT2. For instance, levels of SCG10 in neurites, another short-lived protein involved in Wallerian degeneration (Shin et al. 2012 ) and sporadic ALS (Melamed et al. 2019) , also declined following CCCP administration ( Fig. S1A-D) . However, as it is the case when delivery of all proteins is impaired by axotomy, our data suggest that NMNAT2
is the limiting factor for axonal survival following CCCP-mediated mitochondrial depolarisation. 
Changes in the NMN/NAD ratio following CCCP administration
We have shown that NMNAT2 depletion leads to accumulation of its substrate, NMN, which we suggest promotes axon degeneration , 2017 Loreto et al. 2015) , as well as to NAD depletion, which also plays an important role (Sasaki et al. 2016; Essuman et al. 2017) (Fig. 4A ). Thus, changes in NMN/NAD ratio is an additional indicator of Wallerian pathway activation. We previously reported a marked increase of NMN levels in injured sciatic nerves in vivo (Di Stefano et al. , 2017 . Sasaki and colleagues recently showed a transient increase in NMN levels in sensory neurons after axotomy also in vitro (Sasaki et al. 2016 ). However, selecting the correct time points is difficult due to the substantial cellular material required for the analysis and the rapid degeneration process which compromises the integrity of the plasma membrane, making any measurement unreliable. We therefore tested whether NMN accumulates and NAD declines following mitochondrial depolarisation in Sarm1 -/-SCG neurons, where the degeneration process following CCCP administration is strongly delayed (Fig. 1D,E) .
We looked at 12 hr after CCCP treatment, when wild-type neurites showed the first signs of degeneration (Fig. 2D,E) , reasoning that an increase in NMN levels should have already occurred. We found a 2-fold increase in NMN levels and a more modest decrease in NAD levels in neurites resulting in a robust increase in the NMN/NAD ratio (Fig. 4B) (Fig. S2A) , consistent with the predicted effects of (Fig. S2B) , consistent with levels of NMNAT2 in the soma being less affected after CCCP administration (Fig. 3A,B) and with the presence of nuclear NMNAT1, which will contribute to NMN and NAD homeostasis in this compartment.
Several lines of evidence suggest that NMN accumulation is not simply a marker but is a trigger of axon degeneration. Blocking NMN accumulation with FK866, an inhibitor of the NMN-synthesizing enzyme NAMPT (Fig. 4A) , delays Wallerian degeneration. Exogenous administration of NMN restores its accumulation in the presence of FK866, reverting the protection (Di Loreto et al. 2015) . Also scavenging NMN with expression of bacterial enzyme NMN deamidase, which converts NMN into NaMN (Fig. 4A) , results in strong protection of injured axons in mouse primary neurons and in vivo in mice and zebrafish , 2017 Loreto et al. 2015) . We therefore tested whether NMN accumulation also promotes axon degeneration after CCCP administration. We first confirmed that the levels of NAMPT were not affected by CCCP treatment (Fig. 5A,B ). This is important since NAMPT expression is required for NMN synthesis, which results in the accumulation of NMN in the absence of NMNAT2. We then tested whether blocking NMN synthesis with FK866 delays CCCP-induced axon degeneration. As with axon degeneration after axotomy , FK866 treatment strongly delayed neurite degeneration following CCCP administration. Of note, coadministration of exogenous NMN reverted FK866-induced protection (Fig. 5C,D) . In contrast to our previous findings (Di , some studies reported a protective effect of NMN against axotomy-induced axon degeneration (Sasaki et al. 2006) , possibly due to differences in incubation time of NMN before transection.
Importantly, we confirmed that NMN had no protective effect on the degeneration process when added together with CCCP ( Fig. 5E,F) . NMNAT2 depletion still J o u r n a l P r e -p r o o f occurred in neurites protected by FK866, consistent with its expected protective action downstream of NMNAT2 loss in this situation (Fig. S3A,B ) (Di . FK866 conferred full protection also when added up to 8 hr after CCCP addition (when NMNAT2 levels in neurites are already dramatically reduced) and
halted the progression of the degeneration when added 12 hr after CCCP (when neurites appear already damaged) ( Fig. S3C,D) . This suggests that activation of the pathway might be reversible, or at least the existence of a time window after mitochondrial dysfunction when it can be prevented, which is important in the context of therapeutic intervention in human diseases.
Taken together, these data further support a pro-degenerative role of NMN and are an additional confirmation that CCCP causes axon degeneration through the activation of the Wallerian pathway.
Highwire deficiency rescues loss of a subpopulation of dopaminergic (PPL1) neurons in Pink1 Drosophila mutants
To validate our findings in an in vivo model where mitochondrial dysfunction is caused by a genetic mutation, we employed a Drosophila mutant with a loss-offunction mutation in the PD-associated gene Pink1 (Pink1 B9 ). Pink1 is involved in mitochondrial quality control and mutations in this protein are linked to early-onset recessive PD (Valente et al. 2001 (Valente et al. , 2004 Pickrell and Youle 2015) . Loss of Pink1 in flies leads to severe mitochondrial defects resulting in, among other phenotypes, S4 ).
We first tested whether Highwire deficiency (Hiw N ) could rescue the loss of dopaminergic neurons in the PPL1 cluster ( Fig. 6A ) in Pink1 B9 flies. As Highwire mutants display synaptic overgrowth during development at the neuromuscular junction (Wan et al. 2000) , we first confirmed that the number of dopaminergic neurons in the PPL1 cluster did not differ from wild-type flies (Fig. 6B,C) . Importantly,
Highwire deletion rescued the loss of dopaminergic neurons in the PPL1 cluster ( Fig.   6B,C) . Highwire deletion also significantly prolonged the lifespan of Pink1 B9 flies (Fig.   6D ), but was not sufficient to rescue climbing and flying ability (Fig. 6E,F) , likely due to the widespread muscle degeneration that is also seen in Pink1 B9 flies (Clark et al. 2006; Tain et al. 2009 ). Modulation of the Wallerian pathway thus appears to be protective against neurodegeneration caused by non-toxin models of mitochondrial disruption in flies. Our previous work and that of others suggest a minor contribution of mitochondria to the late stages of Wallerian degeneration after axon transection (Kitay et al. 2013; Loreto et al. 2015) , mainly through the opening of mitochondria permeability transition pore and release of Ca 2+ into the cytoplasm (Barrientos et al. 2011; Villegas et al. 2014) . We now show that mitochondrial dysfunction can impact on the Wallerian pathway in a second way, activating it at an early step upstream of NMNAT2. Crucially, like FK866-protected axons (Loreto et al. 2015) , Sarm1 -/and Wld S axons can be kept morphologically intact for days despite fully depolarised mitochondria (this study and (Summers et al. 2014; Loreto et al. 2015) ). This indicates that WLD S expression and SARM1 deficiency confer protection downstream of mitochondrial impairment (Fig. 7) , rather than directly impacting on mitochondrial health.
The relevance of the Wallerian pathway beyond its role after axotomy is now widely accepted and mitochondrial depolarisation can now be added to a growing list of non-axotomy insults causing Wallerian-like degeneration, including toxicity caused J o u r n a l P r e -p r o o f by chemotherapy agents, chemicals disruption of the nigrostriatal pathway, protein synthesis inhibition and NGF withdrawal (Conforti et al. 2014) . Importantly, most of these studies used either WLD S expression or Sarm1 deletion as means to assess the involvement of Wallerian-like degeneration. However, these proteins are likely to have additional, non-Wallerian pathway functions and could thus confer a protective phenotype independently of the Wallerian pathway. For example, WLD S protection against neuropathy and retinopathy in a streptozotocin-induced mouse model of diabetes is linked to a rescue of pancreatic islets (Zhu et al. 2011 ), likely through a mechanism that is unrelated to its role in axons. Recent steps forward in the understanding of the molecular mechanisms of axon degeneration revealed a welldefined pathway of axon death, with the identification of crucial mechanistic links between NMNAT2 and SARM1 (Gilley et al. 2015 (Gilley et al. , 2017 . The knowledge of a core mechanistic pathway allows multiple stages to be probed when seeking to establish a role for the Wallerian pathway in non-axotomy insults and diseases. Here, we followed this approach focusing on NMNAT2 levels, changes in NMN/NAD ratio and protection conferred by WLD S expression and Sarm1 deletion. This is the first demonstration of Wallerian pathway involvement at multiple steps in a non-axotomy axonal stress.
A next crucial question is whether the activation of the Wallerian pathway contributes (Neukomm et al. 2017) . This is likely because Drosophila only has one NMNAT isoform (compared to three in mammals) and so a reduction in dNMNAT levels cause a more profound damage to the whole cell, rather than predominantly affecting axons (as it is the case with the major axonal isoform, NMNAT2, in mammals). Finally, we cannot fully rule out the possibility that other actions of Highwire contribute to these observations.
Among a number of neurodegenerative disorders associated with mitochondrial dysfunction, the link between PD and axon loss is particularly important. PD involves preferential loss of substantia nigra pars compacta dopaminergic neurons. These neurons have extremely long and branched axons which are lost early in PD patients (Matsuda et al. 2009; Tagliaferro and Burke 2016) , and, as such, may be more vulnerable to axonal stresses. Wallerian-like degeneration has also been implicated in other PD models, with WLD S protecting after MPTP and 6-hydroxydopamine administration (Sajadi et al. 2004; Hasbani and O'Malley 2006; Cheng and Burke 2010) , and with neuroprotection in Pink1 mutant flies by Highwire deficiency that can now be added to the list. However, more comprehensive studies in genetic and chronic models of PD in mammals will be needed to establish whether the Wallerian pathway plays a causative role in PD pathology or simply increases susceptibility to J o u r n a l P r e -p r o o f disease. Interestingly, we also show that lower levels of NMNAT2 make neurites more vulnerable to the consequences of CCCP-induced mitochondrial depolarisation and, as NMNAT2 mRNA levels have been reported to vary hugely in the human population (up to 50-fold differences) (Ali et al. 2016) , some individuals might thus be at a much higher risk of mitochondrial disorders.
CONCLUSIONS
We show that acute mitochondrial impairment induced by CCCP leads to NMNAT2 depletion and subsequent activation of the Wallerian pathway (Fig. 7) , and that loss 
